PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
7 Nov 2019
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinu...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
7 Oct 2019
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
7 Oct 2019
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Irela...
7 Oct 2019
Lutetium-177 PSMA scanning for prostate cancer
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
4 Oct 2019
Optimal timing of radiotherapy following radical prostatectomy
Prof Chris Parker - The Royal Marsden Hospital, London, UK
4 Oct 2019
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal
2 Oct 2019
Role of molecular diagnostics in prostate cancer
Dr Elena Castro and Dr Shahneen Sandhu
2 Oct 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
30 Sep 2019
Bladder cancer: Latest advances in targeted therapies and precision medicine fro...
Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr...
30 Sep 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
